Teva Pharmaceutical Industries Limited
A maker of generic medicines, biosimilars, and brand-name drugs, Teva is one of the world's largest generic drugmakers. Its products treat conditions like multiple sclerosis (COPAXONE), migraine (AJOVY), and Huntington's chorea (AUSTEDO), used by patients and health systems worldwide. Founded in 1901 in Jerusalem as a small medicine wholesaler that shipped goods by mule and camel, it took the name "Teva"—the Hebrew word for "nature"—in the 1930s.
American Depositary Receipt (ADR) representing 1 ordinary share of Teva Pharmaceutical Industries Ltd
Granted 14.5K
Granted 1.85M · Sold 940.3K
Granted 14.5K · Sold 327.4K
Granted 21.7K
Granted 14.5K
Granted 14.5K
Granted 14.5K
Granted 14.5K
Granted 209.3K · Sold 101.6K
Granted 352.9K · Sold 423.2K
Granted 14.5K
Granted 268.0K · Sold 605.6K
Granted 101.8K · Sold 96.5K
Granted 390.5K · Sold 383.1K
Granted 85.8K · Sold 41.7K
Granted 14.2K · Sold 14.2K
Granted 25.0K · Sold 35.3K
Granted 19.3K
Bought 1.1K
Granted 15.3K · Sold 5.1K
Granted 33.5K · Sold 43.5K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Elstein AmirDirector · 1 transaction | +0.7% | 2.12M | 14.5K | — | — |
| Francis Richard DPresident and CEO · 14 transactions | +335.5% | 1.18M | 1.85M | — | 940.3K |
| Mignone RobertoDirector · 4 transactions | -39.1% | 487.4K | 14.5K | — | 327.4K |
| Barer Sol JDirector · 1 transaction | +5.1% | 448.0K | 21.7K | — | — |
| Lieberman Gerald MDirector · 1 transaction | +12.5% | 130.1K | 14.5K | — | — |
| Crane Rosemary ADirector · 1 transaction | +12.8% | 127.7K | 14.5K | — | — |
| Nisen PerryDirector · 1 transaction | +13.8% | 119.8K | 14.5K | — | — |
| Satchi-Fainaro RonitDirector · 1 transaction | +14.8% | 112.4K | 14.5K | — | — |
| Hughes Eric ASee "Remarks" · 8 transactions | +104.2% | 107.7K | 209.3K | — | 101.6K |
| Sabag MarkSee "Remarks" · 10 transactions | -46.5% | 80.8K | 352.9K | — | 423.2K |
| Zaks Tal ZviDirector · 1 transaction | +24.7% | 73.3K | 14.5K | — | — |
| Kalif Eliyahu SharonEVP, Chief Financial Officer · 8 transactions | -83.7% | 65.6K | 268.0K | — | 605.6K |
| Fox ChristineEVP, U.S. Commercial · 8 transactions | +9% | 63.6K | 101.8K | — | 96.5K |
| Daniell RichardEVP, Europe Commercial · 15 transactions | -42.4% | 55.8K | 390.5K | — | 383.1K |
| Lippman EvanEVP, Business Development · 4 transactions | — | 44.2K | 85.8K | — | 41.7K |
| Jover PlacidSee "Remarks" · 2 transactions | +63.1% | 20.9K | 14.2K | — | 14.2K |
| Weiss AmirChief Accounting Officer · 7 transactions | -33.8% | 20.0K | 25.0K | — | 35.3K |
| Lichtenstein ChenDirector · 2 transactions | — | 19.3K | 19.3K | — | — |
| McAvoy David R.EVP, Chief Legal Officer · 1 transaction | +9.3% | 13.0K | — | 1.1K | — |
| Savage BrianInterim Chief Legal Officer · 8 transactions | — | 10.9K | 15.3K | — | 5.1K |
| Shields MatthewEVP, Global Operations · 5 transactions | -100% | 0 | 33.5K | — | 43.5K |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last year: -3.02M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.